LGALS9 and neoplasm: Recently, a novel biomarker on the galectin-9 binding partner, T cell immunoglobulin mucin-3 (TIM-3), was found to be upregulated in response to anti-PD-1 therapy and has been targeted as a novel immune checkpoint in tumor immunotherapy [51].